Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine – a Phase I trial

Sylvia Guetz, Amanda Tufman, Joachim von Pawel, Achim Rittmeyer, Astrid Borgmeier, Pierre Ferré, Birgit Edlich, Rudolf Maria Huber
  • OncoTargets and Therapy, February 2017, Dove Medical Press
  • DOI: 10.2147/ott.s122106

Metronomic therapy of NSCLC with vinorelbine

What is it about?

Metrinomic therapy is underevaluated in lung cancer. Oral drugs like vinorelbine allow continous daily dosing in an outpatient setting. We established a recommended dose and showed preliminary efficacy in heavily pretreated patients with NSCLC

Why is it important?

Metronomic application of daily oral vinorelbine offers a further treatment options in advanced pretreated patients with NSCLC

Perspectives

Professor Rudolf M. Huber
University of Munich and Thoracic Oncology Centre Munich

Metronomic oral daily application allows variable and adjusted tretment. It could also be integrated in simultaneous radiochemotherapy schedules.

open access logoRead Publication

http://dx.doi.org/10.2147/ott.s122106

The following have contributed to this page: Dr. Birgit Edlich and Professor Rudolf M. Huber